These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8854231)

  • 1. The effects of treatment noncompliance on power in a 2 x 2 factorial design.
    Lindblad AS
    J Biopharm Stat; 1996 Jul; 6(3):263-70. PubMed ID: 8854231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation.
    Greenland S; Lanes S; Jara M
    Clin Trials; 2008; 5(1):5-13. PubMed ID: 18283074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noncompliance in cancer screening trials.
    Gareen IF
    Clin Trials; 2007; 4(4):341-9. PubMed ID: 17848495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of non-compliance on intent-to-treat analysis of equivalence trials.
    Sheng D; Kim MY
    Stat Med; 2006 Apr; 25(7):1183-99. PubMed ID: 16220491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, analysis and presentation of factorial randomised controlled trials.
    Montgomery AA; Peters TJ; Little P
    BMC Med Res Methodol; 2003 Nov; 3():26. PubMed ID: 14633287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical analysis of clinical trials.
    Wassertheil-Smoller S; Kim MY
    Semin Nucl Med; 2010 Sep; 40(5):357-63. PubMed ID: 20674595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination for testing equality in a cluster randomized trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2011 Jan; 21(1):1-17. PubMed ID: 21191850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
    Licciardone JC; Russo DP
    J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discussion of "Identifiability and estimation of causal effects in randomized trials with noncompliance and completely nonignorable missing data".
    Small DS; Cheng J
    Biometrics; 2009 Sep; 65(3):682-6; discussion 689-91. PubMed ID: 18759846
    [No Abstract]   [Full Text] [Related]  

  • 11. Test non-inferiority and sample size determination based on the odds ratio under a cluster randomized trial with noncompliance.
    Lui KJ; Chang KC
    J Biopharm Stat; 2011 Jan; 21(1):94-110. PubMed ID: 21191857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of statistical methods for analysing survival data in the presence of non-random compliance.
    Odondi L; McNamee R
    Stat Med; 2010 Dec; 29(29):2994-3003. PubMed ID: 20963732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testing homogeneity of the risk ratio in stratified noncompliance randomized trials.
    Lui KJ
    Contemp Clin Trials; 2007 Sep; 28(5):614-25. PubMed ID: 17409026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation in survival trials accounting for time-varying relationship between noncompliance and risk of outcome event.
    Li B; Grambsch P
    Clin Trials; 2006; 3(4):349-59. PubMed ID: 17060209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.
    Brookes ST; Whitely E; Egger M; Smith GD; Mulheran PA; Peters TJ
    J Clin Epidemiol; 2004 Mar; 57(3):229-36. PubMed ID: 15066682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of poor compliance and treatment side effects on sample size requirements in randomized clinical trials.
    Schechtman KB; Gordon MO
    J Biopharm Stat; 1994 Jul; 4(2):223-32. PubMed ID: 7951277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weighting in instrumental variables and G-estimation.
    Joffe MM; Brensinger C
    Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dichotomizing partial compliance and increased participant burden in factorial designs: the performance of four noncompliance methods.
    Merrill PD; McClure LA
    Trials; 2015 Nov; 16():523. PubMed ID: 26573840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regarding paper "Five interval estimators for proportion ratio under a stratified randomized clinical trial with noncompliance" by Lui K. J. and Chang K. C.
    Vach W
    Biom J; 2007 Aug; 49(4):627-9; author reply 630-1. PubMed ID: 17722194
    [No Abstract]   [Full Text] [Related]  

  • 20. Noncompliance in lifestyle intervention studies: the instrumental variable method provides insight into the bias.
    Hertogh EM; Schuit AJ; Peeters PH; Monninkhof EM
    J Clin Epidemiol; 2010 Aug; 63(8):900-6. PubMed ID: 20189770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.